Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.

Ramli A, Aljunid SM, Sulong S, Md Yusof FA.

Ther Clin Risk Manag. 2013;9:491-504. doi: 10.2147/TCRM.S52078. Epub 2013 Dec 4.

2.

Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.

Al-Badriyeh D, Fahey M, Alabbadi I, Al-Khal A, Zaidan M.

Clin Ther. 2015 Dec 1;37(12):2798-810. doi: 10.1016/j.clinthera.2015.07.020. Epub 2015 Aug 20.

PMID:
26299479
3.

Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.

Zhou YT, Yu LS, Zeng S, Huang YW, Xu HM, Zhou Q.

Ther Clin Risk Manag. 2014;10:17-26. doi: 10.2147/TCRM.S55512. Epub 2013 Dec 20. Review.

4.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
5.
6.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
7.

A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.

Wilson K, Marriott J, Fuller S, Lacey L, Gillen D.

Pharmacoeconomics. 2003;21 Suppl 1:1-11.

PMID:
12648030
8.

A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.

Tárraga-López PJ, Celada-Rodríguez A, Cerdán-Oliver M, Solera-Albero J, Ocaña-López JM, López-Cara MA, De Miguel-Clave J.

Pharmacoeconomics. 2005;23(3):275-87. Erratum in: Pharmacoeconomics. 2006;24(1):106.

PMID:
15836008
9.

Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.

Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, O'Donnell JC.

Value Health. 2005 Nov-Dec;8(6):618-28.

10.

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

Yee HS, Fong NT.

Ann Pharmacother. 1998 Oct;32(10):1030-43. Review.

PMID:
9793596
11.

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Lennernäs H, Fager G.

Clin Pharmacokinet. 1997 May;32(5):403-25. Review.

PMID:
9160173
12.

A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.

Hoffman KB, Kraus C, Dimbil M, Golomb BA.

PLoS One. 2012;7(8):e42866. doi: 10.1371/journal.pone.0042866. Epub 2012 Aug 22.

13.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
14.

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Chauvin B, Drouot S, Barrail-Tran A, Taburet AM.

Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. Review.

PMID:
23703578
15.
16.

Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.

Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.

Clin Ther. 1999 Nov;21(11):1924-36.

PMID:
10890264
17.

The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.

Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, Schrott HG, Henley RW Jr, Tresh P, McLain RW, Bakker-Arkema RG, Black DM.

Pharmacoeconomics. 1998 Jul;14(1):59-70.

PMID:
10182195
18.

Pharmacological comparison of the statins.

Klotz U.

Arzneimittelforschung. 2003;53(9):605-11. Review.

PMID:
14558433
19.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
20.

Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.

Al-Badriyeh D, Alabbadi I, Fahey M, Al-Khal A, Zaidan M.

Clin Ther. 2016 May;38(5):1158-73. doi: 10.1016/j.clinthera.2016.03.004. Epub 2016 Mar 25.

PMID:
27021610

Supplemental Content

Support Center